Matthew Herper at Forbes argues that the biotech boom of the past two years has been spurred by new drug launches and research breakthroughs. However, he cautions that some investors are currently "seeing rainbows and missing the rain."
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: caution urged in use of gene drives, and more.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."